{"pub_date": "2016-07-05T00:00:00Z", "subsection_name": null, "lead_paragraph": "A California initiative meant to lower skyrocketing prescription drug prices faces opposition from not only drug makers but also some patient advocacy groups.", "print_page": "1", "document_type": "article", "byline": {"contributor": "", "person": [{"rank": 1, "organization": "", "lastname": "POLLACK", "firstname": "Andrew", "role": "reported"}], "original": "By ANDREW POLLACK"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/06/30/business/01DRUGS/01DRUGS-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/06/30/business/01DRUGS/01DRUGS-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 399, "url": "images/2016/06/30/business/01DRUGS/01DRUGS-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "399", "xlarge": "images/2016/06/30/business/01DRUGS/01DRUGS-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/06/30/business/01DRUGS/01DRUGS-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/06/30/business/01DRUGS/01DRUGS-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "Drug Price Plan Has Surprising Opposition", "main": "California Drug Price Plan Is Criticized by Patient Advocates"}, "source": "The New York Times", "blog": [], "word_count": "1324", "web_url": "http://www.nytimes.com/2016/07/05/business/california-drug-price-plan-is-criticized-by-patient-advocates.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "A California initiative meant to lower skyrocketing prescription drug prices faces opposition from not only drug makers but also some patient advocacy groups....", "_id": "577ad2f738f0d83e1f65d6e2", "abstract": "Several patient advocacy groups have emerged as unlikely opponents of California ballot initiative aimed at reducing prescription drug prices; say plan will be difficult to implement and could inadvertently lead to higher prices as pharmaceutical companies seek to outmaneuver restrictions. ", "keywords": [{"rank": "1", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N"}, {"rank": "3", "name": "glocations", "value": "California", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Referendums", "is_major": "Y"}, {"rank": "5", "name": "subject", "value": "Health Insurance and Managed Care", "is_major": "N"}]}